SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2021
2020
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
Press Releases
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
10/13/2021
Year-End Report 20/21
10/12/2021
Clinical results with Diamyd Medical’s study drug Remygen
®
published in scientific journal
10/11/2021
The diabetes vaccine Diamyd
®
to be featured in two oral presentations at the International Diabetes Federation Congress
9/23/2021
Diamyd Medical and partners are awarded SEK 40 million in VINNOVA funding for the prevention of autoimmune diseases
9/23/2021
A new analysis that supports the effect of the diabetes vaccine Diamyd
®
will be presented at a scientific conference on 13 October
9/21/2021
Diamyd Medical receives first regulatory approval to start the Phase III trial DIAGNODE-3 with the diabetes vaccine Diamyd
®
9/17/2021
FDA pauses start of DIAGNODE-3 in the US pending clarification on study drug
9/15/2021
Diamyd Medical acquires property with manufacturing facility in Umeå, Sweden
9/10/2021
Diamyd Medical changes date for publication of year-end report
9/9/2021
Diamyd Medical carries out a directed share issue and raises proceeds of SEK 150 million
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research